BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33039120)

  • 1. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study].
    Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B
    Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
    Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
    Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
    Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin-aldosterone system and COVID-19 infection.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
    Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
    Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
    Li J; Wang X; Chen J; Zhang H; Deng A
    JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
    JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
    Pirola CJ; Sookoian S
    J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
    Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
    Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
    Georges JL; Gilles F; Cochet H; Bertrand A; De Tournemire M; Monguillon V; Pasqualini M; Prevot A; Roger G; Saba J; Soltani J; Koukabi-Fradelizi M; Beressi JP; Laureana C; Prost JF; Livarek B
    PLoS One; 2020; 15(12):e0244349. PubMed ID: 33347477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients.
    Genet B; Vidal JS; Cohen A; Boully C; Beunardeau M; Marine Harlé L; Gonçalves A; Boudali Y; Hernandorena I; Bailly H; Lenoir H; Piccoli M; Chahwakilian A; Kermanach L; de Jong L; Duron E; Girerd X; Hanon O
    J Am Med Dir Assoc; 2020 Nov; 21(11):1539-1545. PubMed ID: 33138935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
    Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
    Kurdi A; Abutheraa N; Akil L; Godman B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19.
    Negreira-Caamaño M; Piqueras-Flores J; Martínez-DelRio J; Nieto-Sandoval-Martin-DeLaSierra P; Aguila-Gordo D; Mateo-Gomez C; Salas-Bravo D; Rodriguez-Martinez M; Negreira-Caamaño M
    High Blood Press Cardiovasc Prev; 2020 Dec; 27(6):561-568. PubMed ID: 32949380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
    Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
    J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
    Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
    Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
    Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
    PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.